The autonomous driving software provider completed a series B round led by BP Ventures that also featured corporate investors Tencent and Halma.
Author: Thierry Heles
Amgen adds capital to DJS Antibodies
Amgen has participated in an $8.4m round for the antibody therapeutics developer, which aims to tackle chronic kidney disease.
Mobilion roars to $35m series B
Agilent returned for a round that pushed the medical device developer’s overall funding past the $50m mark and which will go to commercialising its Slim technology.
SiFive slides into $61m
Qualcomm Ventures, Western Digital Capital and Intel Capital all returned for the customer chipmaker’s series E round, which was led by SK Hynix.
Gentex absorbs Vaporsens
University of Utah spinout Vaporsens has been acquired by Gentex for $10.5m after the corporate had supplied $3m in equity financing.
QuantumCTek cultivates $102m IPO
Legend Capital-backed quantum computing technology developer QuantumCTek has filed to raise up to $102m in an initial public offering in Shanghai.
Fusion Pharmaceuticals to mingle with public markets
Johnson & Johnson and Varian Medical Systems are in line for exits after cancer therapy developer Fusion filed for a $100m initial public offering.
Avectas accesses $20m
Emergent BioSolutions-backed Avectas has added $20m to its coffers to help drug developers create cancer treatments.
PsiQuantum processes $215m
M12 participated in a round for University of Bristol spinout PsiQuantum, which is developing a quantum computer system.
Passage Bio amasses $248m for IPO close
The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.
ABB annexes Cylon Controls
The HVAC control system provider has agreed to a purchase by ABB that will allow ESB Novusmodus Fund to exit six years after its investment.
Passage Bio leads investors to $216m IPO
The Access Industries and Eli Lilly-backed genetic drug developer floated at the top of its range having increased the number of shares in the offering by 60%.
MRM Health embeds $15m
MRM Technologies has spun off inflammatory bowel disease drug developer MRM Health with $15m from investors including strategic partner DuPont.
Stilla stacks up series B funding
Illumina Ventures returned to reinvest in a $21.8m round for the DNA-analysis system developer having led its series A round in 2018.